PDS Biotechnology Corporation reported full year 2025 net loss of $34.5 million and cash balance of $26.7 million as of December 31, 2025, alongside VERSATILE-003 Phase 3 trial amendment incorporating PFS as interim endpoint.
Key takeaways
Net loss for year ended December 31, 2025 was $34.5 million or $0.74 per share vs $37.6 million or $1.03 per share in 2024
Research and development expenses decreased to $19.0 million from $22.6 million in 2024
Cash balance was $26.7 million as of December 31, 2025
Amended VERSATILE-003 Phase 3 protocol to use PFS as interim primary endpoint for accelerated approval of PDS0101 in HPV16-positive head and neck cancer
PDS01ADC with docetaxel showed median PFS of 9.6 months in NCI-led mCRPC trial
New U.S. and Japan patents for PDS0101 extend protection into 2040s